Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature

Jingyu Zhong; Yangfan Hu; Liping Si; Jia Geng; Yue Xing; Qiong Jiao; Huizhen Zhang; Weiwu Yao

doi:10.1016/j.jbo.2020.100305

Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature

J Bone Oncol. 2020 Jul 15:24:100305. doi: 10.1016/j.jbo.2020.100305. eCollection 2020 Oct.

Authors

Jingyu Zhong¹, Yangfan Hu², Liping Si¹, Jia Geng², Yue Xing², Qiong Jiao³, Huizhen Zhang³, Weiwu Yao¹

Affiliations

¹ Department of Imaging, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200050, China.
² Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
³ Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.

Abstract

Introduction: Small cell osteosarcoma (SCOS) is a rare subtype of osteosarcoma, with limited studies mainly focusing on histological features. Our study aims to analyze our own patients and those reported in the literature to increase the recognition of this rare disease, to evaluate patient survival and to further determine potential prognostic factors.

Material and methods: Twenty patients with SCOS were treated in our hospital between 2010 and 2019. Their follow-up data were collected retrospectively. A total of 336 literature cases from 58 manuscripts were retrieved by means of a PubMed search with the key word "small cell osteosarcoma". Data pertaining to treatment and follow-up were extracted. We performed a pooled analysis for the survival of patients and the risk factors for local recurrence (LR), as well as metastatic disease (MD), in a total of 160 patients using the Kaplan-Meier method and Cox regression method.

Results: We reported our experience in diagnosing and treating SCOS. In our cases, elevated alkaline phosphatase (P = 0.013) and lactate dehydrogenase (P = 0.001) significantly impaired overall survival. In the pooled analysis, SCOS was diagnosed at the median age of 17 years and affected both sexes almost equally. The median follow-up duration was 19.5 months. In the pooled analysis cases, the 5-year overall survival rate was 38.6%, and 36.4% of patients survived 10 years. However, an increasing trend was detected, indicating recent improvements in management. The surgical margin status (P = 0.024) and metastases (P = 0.008) significantly impaired overall survival, and the response to chemotherapy was related to disease-free survival (P = 0.012). LR and MD were significantly correlated (P = 0.002) and could be observed after 5 years of follow-up. LR was significantly dependent on response to chemotherapy (P = 0.020). The development of MD seemed to be affected by response to chemotherapy (P = 0.060). Correlations between imaging features and prognosis were not detected.

Conclusions: This study suggested that positive margins, poor response to chemotherapy and MD are negative prognostic factors for SCOS, implied the potential role of laboratory examinations in the survival prediction and supported the need for prolonged or more intensive surveillance in patients with MD or LR. More well-documented literatures are encouraged to allow further confirmations.

Keywords: ALP, alkaline phosphatase; CT, computed tomography; DFS, disease-free survival; LDH, lactate dehydrogenase; LR, local recurrence; MD, metastatic disease; MRI, magnetic resonance imaging; Metastasis; Neoadjuvant chemotherapy; OS, overall survival; Recurrence; SCOS, small cell osteosarcoma; Small cell osteosarcoma; Surgical margin; Survival.